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Since 2002, there has been a gradual worldwide 1.3% annual decrease in the incidence of
tuberculosis (TB). This is an encouraging statistic; however, it will not achieve the World
Health Organization’s goal of eliminating TB by 2050, and it is being compounded by the
persistent global incidence of drug-resistant tuberculosis (DR-TB) acquired by transmission
and by treatment pressure. One key to effectively control tuberculosis and the spread of
multiresistant strains is accurate information pertaining to drug resistance and suscepti-
bility. Next-generation sequencing (NGS) has the potential to effectively change global
health and the management of TB. Industry has focused primarily on using NGS for oncol-
ogy diagnostics and human genomics, but the area in which NGS can rapidly impact health
care is in the area of infectious disease diagnostics in low- and middle-income countries.
To date, there has been a failure as a community to capitalize on the potential of NGS, espe-
cially at the reference laboratory level where it can provide actionable information pertain-
ing to treatment options for patients. The rapid evolution of knowledge about the genetic
foundations of tuberculosis drug resistance makes sequencing a versatile technology plat-
form for providing rapid, accurate, and actionable results for treating this disease. No
‘‘plug-and-play” and ‘‘end-to-end” NGS solutions exist that provide clinically relevant
sequence data from the Mycobacterium tuberculosis complex genome from primary clinical
samples (e.g., sputum) in high-burden country reference laboratories, which is where they
are most needed. However, such a system-based solution is underdeveloped by Foundation
for Innovative Diagnostics (FIND), in collaboration with partners from academia, non-
governmental organizations, and industry. The solution is modular and is designed and
developed to perform targeted amplicon sequencing directly from a patient’s primary spu-
tum sample. This solution will initially allow reference laboratories to perform reflex NGS
that provides a rapid and comprehensive analysis of a patient’s M. tuberculosis complex
drug resistance profile, thereby facilitating optimization of a patient’s treatment, improving
treatment outcomes, and reducing the spread of DR-TB. Such a system could also enable
countries to implement culture-free drug resistance surveillance programs, which could
bypass the need for expensive culture facilities, decrease a country’s dependence on exter-
nal laboratories, and significantly expand the map of global surveillance capabilities. Inberculosis
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diagnosis: A promise for the near future. Int. Jaddition, the introduction of such a system will provide a foundation for NGS to be used for
genotypic testing for human immunodeficiency virus-infected patients, surveillance of
other diseases, in-country capability for outbreak discovery and management, and a host
of other diagnostic benefits that are currently limited to high-income countries.Conflicts of interest
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